Oncopeptides AB represents a commitment to developing innovative therapies for hematological diseases, particularly multiple myeloma. The company's corporate philosophy focuses on patients' needs, striving to improve their quality of life through effective treatment options. Oncopeptides AB prides itself on scientific expertise, leveraging advanced research techniques to create targeted and personalized therapies. The company values inclusivity, fostering collaboration among healthcare professionals, researchers, and patients to drive advancements in cancer care. Oncopeptides AB aims to make a positive impact in the medical community by continuously pushing the boundaries of medical science and delivering novel solutions for patients battling hematological malignancies.

Oncopeptides AB is primarily present in several countries and regions. The company is based in Sweden and has a significant presence in Europe, including Denmark, Finland, France, Germany, Italy, the Netherlands, Norway, and Spain. Additionally, Oncopeptides AB has expanded its reach to the United States and Canada, demonstrating its global presence. With a focus on developing and commercializing innovative treatments for hematological malignancies, Oncopeptides AB continues to establish a strong presence in key markets worldwide.

Oncopeptides AB has achieved significant milestones in the field of oncology. The company successfully developed and gained approval for its lead product, melflufen, a peptide-drug conjugate specifically designed to target and treat multiple myeloma. Oncopeptides AB also completed a successful initial public offering (IPO) on the NASDAQ Stockholm stock exchange, which further strengthened its financial position. The company has expanded its global footprint by establishing subsidiaries and commercialization agreements. Furthermore, Oncopeptides AB has received several regulatory designations and grants to support the development and commercialization of their products. These milestones highlight the company's commitment to making a difference in the lives of patients and advancing cancer treatments.

Oncopeptides AB is a biopharmaceutical company focusing on the development of innovative treatments for hematological cancers. Founded in 2000 and headquartered in Stockholm, Sweden, the company has a strong commitment to improving the lives of patients with multiple myeloma and other hematological malignancies. Oncopeptides AB's flagship product is melflufen, which is a first-in-class peptide-drug conjugate designed to target and eradicate cancer cells. Through extensive research and collaborations, the company has made significant advancements in the field of oncology, positioning itself as a leading player in the development of novel therapies for hematological cancers. Oncopeptides AB's dedication to scientific innovation and patient-centered approach has propelled its growth and position in the market.

There are several main competitors of Oncopeptides AB in the market. Some notable competitors include Celgene Corporation, Amgen Inc., Bristol-Myers Squibb Company, and Johnson & Johnson. These companies are also active in the field of oncology and focus on developing innovative treatments for cancer. Oncopeptides AB faces competition in the market from both established pharmaceutical companies as well as emerging biotechnology firms. It is important for Oncopeptides to stay vigilant and continuously strive to differentiate their products and maintain a competitive edge in this highly dynamic industry.

Oncopeptides AB is primarily active in the pharmaceutical and biotechnology industries.

The business model of Oncopeptides AB focuses on developing and commercializing targeted therapies for the treatment of hematological malignancies. The company specializes in novel drugs based on the proprietary technology platform, called PEPSTATM, which targets and inhibits enzymes that are crucial for the survival and proliferation of cancer cells. Oncopeptides AB aims to provide effective and safe treatment options for patients with unmet medical needs, particularly those with multiple myeloma. By leveraging its innovative platform and expertise in precision medicine, Oncopeptides AB is dedicated to improving outcomes and quality of life for individuals battling hematological cancers.

Az Oncopeptides P/E mutatója -2,43.

Az Oncopeptides KUV 1,73.

Az AlleAktien Minőségi Score Oncopeptides esetében 2/10.

A várt Oncopeptides forgalma 111,66 Mió. SEK.

A(z) várt Oncopeptides nyereség -79,54 Mió. SEK.

Oncopeptides AB is a leading biotechnology company specializing in the development of therapies for cancer. The company was founded in 2000 and is headquartered in Stockholm, Sweden. Oncopeptides is listed on the Nasdaq Stockholm and currently employs nearly 200 employees. The company aims to develop and market innovative therapies for cancer patients. Oncopeptides works closely with medical experts to ensure that the developed therapies meet the unmet needs of cancer patients. The company has extensive experience and knowledge in the development of drugs for rare cancers such as multiple myeloma (MM), a malignancy of the plasma cell system. Oncopeptides' main product line is the development of peptide drugs. Peptide drugs have gained importance in recent years due to their ability to selectively target cancer cells. Oncopeptides has developed a groundbreaking peptide drug platform called PEPIDESCAN to identify and optimize new peptide-based drugs. PEPIDESCAN allows Oncopeptides to improve the selectivity of peptide drugs while increasing their effectiveness. Oncopeptides currently has two important products: PEPAXTO and Melflufen. PEPAXTO, a peptide-based inhibitor developed by Oncopeptides, is the first peptide drug approved by the US Food and Drug Administration (FDA) for multiple myeloma. PEPAXTO has been approved for the treatment of adult patients with relapsed or refractory MM. It is an oral therapy that patients can take at home, improving their quality of life. Melflufen is Oncopeptides' second and newest product. It is a peptide-based drug specifically developed for the treatment of patients with relapsed and refractory MM. Melflufen aims to improve the treatment of patients who do not respond to conventional therapies. Oncopeptides successfully conducted a Phase II study testing Melflufen in combination with dexamethasone in patients with relapsed MM. The results showed promising efficacy and tolerability. Oncopeptides also has an extensive pipeline program, including several peptide-based drugs for various types of cancer. The company has entered partnerships with several leading biotech companies and institutions to expand its research activities and further enhance its pipeline. Overall, Oncopeptides' business model is focused on the development and commercialization of innovative therapies for cancer, particularly for rare cancers such as myeloma. The company has developed a groundbreaking peptide drug platform to identify and optimize new peptide-based drugs. With PEPAXTO and Melflufen, the company already has two successful products on the market. Oncopeptides' pipeline program includes additional peptide-based drugs for various types of cancer that have shown promising results in early clinical studies. Oncopeptides is also committed to expanding its business through partnerships to further enhance its research and development activities.

A(z) Oncopeptides évente alkalommal oszt ki 0 SEK összegű osztalékot.

A Oncopeptides esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Oncopeptides ISIN kódja: SE0009414576.

A Oncopeptides WKN-je A2DLU2.

Az Oncopeptides tőzsdei rövidítése ONCO.ST.

Az elmúlt 12 hónapban a(z) Oncopeptides osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Oncopeptides várhatóan 0 SEK összegű osztalékot fog fizetni.

A(z) Oncopeptides jelenlegi osztalékhozama .

A(z) Oncopeptides negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Oncopeptides az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 SEK összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Oncopeptides a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Oncopeptides által 2025. 01. 08.-án/én fizetett 0 SEK összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2025. 01. 08.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2025. 01. 08. időpontban történt.

2024 évben a Oncopeptides 0 SEK összegű osztalékot fizetett ki.

Az Oncopeptides osztalékait SEK fizeti ki.